Interleukin-8: A potent promoter of angiogenesis in gastric cancer

Shi,Jun; Wei,Pin‑Kang

doi:10.3892/ol.2015.4035

Interleukin-8: A potent promoter of angiogenesis in gastric cancer

Authors:
- Jun Shi
- Pin‑Kang Wei
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai 200003, P.R. China
Published online on: December 15, 2015 https://doi.org/10.3892/ol.2015.4035
Pages: 1043-1050

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis is a critical process in the development of tumor malignancy and occurs at various stages of tumor progression. Interleukin-8 (IL-8) is a pro-angiogenic factor produced by tumor‑infiltrating macrophages that has been revealed to facilitate the development of angiogenesis in various cancers. However, whether IL‑8 activates angiogenesis in gastric cancer remains unclear. The present study investigated the effect of IL‑8 on the migration and canalization capacities of human umbilical vein endothelial cells (HUVECs). In addition, the protein and messenger RNA (mRNA) expression of selected angiogenesis markers, consisting of vascular endothelial growth factor (VEGF)‑A, VEGF receptor (VEGFR)‑1 and VEGFR‑2, were assessed in the HUVECs. The HUVECs were co‑cultured with human gastric cancer SGC7901 cells and exposed to various concentrations of IL‑8 (0, 0.2, 0.5, 0.8 and 1.0 ng/ml). The migration and canalization abilities of the cells were detected by Transwell chamber and tube formation assays. Protein expression was detected using immunofluorescence and western blot analysis, and mRNA levels were assessed using reverse transcription quantitative polymerase chain reaction. The protein and mRNA levels of VEGF‑A, VEGFR‑1 and VEGFR‑2 were measured in HUVECs cultured for 24 h. IL‑8 at concentrations of 0.5, 0.8 and 1.0 ng/ml significantly promoted HUVEC cell migration (P=0.005, P=0.001 and P<0.001, respectively) and tube formation (P=0.039, P=0.003 and P<0.001, respectively). IL‑8 at concentrations of 0.2, 0.5, 0.8 and 1.0 ng/ml significantly elevated the protein levels of VEGF‑A (P<0.001) and VEGFR‑2 (P=0.034, P<0.001, P<0.001 and P<0.001, respectively). IL‑8 at concentrations of 0.8 and 1.0 ng/ml significantly elevated the protein levels of VEGF‑1 (P=0.037 and P=0.002, respectively). Similarly, IL‑8 at concentrations of 0.5, 0.8 and 1.0 ng/ml significantly upregulated the mRNA levels of VEGF‑A (P=0.046, P=0.001 and P<0.001, respectively) and VEGFR‑1 (P=0.042, P<0.001 and P<0.001, respectively). IL‑8 at concentrations of 0.2, 0.5, 0.8 and 1.0 ng/ml significantly upregulated the mRNA levels of VEGFR‑2 (P=0.003, P=0.005, P<0.001 and P<0.001, respectively). In conclusion, IL‑8 may be a potent promoter of angiogenesis in gastric cancer.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide. (11)http://globocan.iarc.fr/Accessed. August 08–2014
3	Suh YS and Yang HK: Screening and early detection of gastric cancer: East versus west. Surg Clin North Am. 95:1053–1066. 2015. View Article : Google Scholar : PubMed/NCBI
4	GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Paoletti X, Oba K, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
5	Folkman J: Angiogenesis in cancer vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
6	Carmeliet P and Jain RK: Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 10:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
7	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
8	Saito H and Tsujitani S: Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma. Anticancer Res 21 (6B). 4365–4372. 2001.
9	Folkman J: Angiogenesis: A n organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
10	Patel-Hett S and D'Amore PA: Signal transduction in vasculogenesis and developmental angiogenesis. Int J Dev Biol. 55:353–363. 2011. View Article : Google Scholar : PubMed/NCBI
11	De Spiegelaere W, Casteleyn C, Van den Broeck W, et al: Intussusceptive angiogenesis: A biologically relevant form of angiogenesis. J Vasc Res. 49:390–404. 2012. View Article : Google Scholar : PubMed/NCBI
12	Koch S: Neuropilin signalling in angiogenesis. Biochem Soc Trans. 40:20–25. 2012. View Article : Google Scholar : PubMed/NCBI
13	Tung JJ, Tattersall IW and Kitajewski J: Tips, stalks, tubes, Notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis. Cold Spring Harb Perspect Med. 2:a0066012012. View Article : Google Scholar : PubMed/NCBI
14	Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
15	Takagi A, Kamiya S, Koga Y, et al: Analysis of interleukin-8 secretion induced by Helicobacter pylori from the gastric epithelial cell line MKN45: A mechanism independent of the intensity of cytotoxicity. J Gastroenterol Hepatol. 12:368–372. 1997. View Article : Google Scholar : PubMed/NCBI
16	Koch AE, Polverini PJ, Kunkel SL, et al: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 258:1798–1801. 1992. View Article : Google Scholar : PubMed/NCBI
17	Strieter RM, Kunkel SL, Elner VM, et al: Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol. 141:1279–1284. 1992.PubMed/NCBI
18	Nomura T, Morishita A, Jian G, et al: Expression of angiogenic factors in hepatocarcinogenesis: Identification by antibody arrays. Oncol Rep. 30:2476–2480. 2013.PubMed/NCBI
19	Akiba J, Yano H, Ogasawara S, Higaki K and Kojiro M: Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol. 18:257–264. 2001.PubMed/NCBI
20	Sales KJ, Sutherland JR, Jabbour HN and Katz AA: Seminal plasma induces angiogenic chemokine expression in cervical cancer cells and regulates vascular function. Biochim Biophys Acta. 1823:1789–1795. 2012. View Article : Google Scholar : PubMed/NCBI
21	Torisu H, Ono M, Kiryu H, et al: Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1alpha. Int J Cancer. 85:182–188. 2000. View Article : Google Scholar : PubMed/NCBI
22	Yoshizaki T, Horikawa T, Qing-Chun R, et al: Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res. 7:1946–1951. 2001.PubMed/NCBI
23	Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar : PubMed/NCBI
24	Ferrara N: Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 29:789–791. 2009. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−∆∆CT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Meadows KL and Hurwitz HI: Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med. 2:a0065772012. View Article : Google Scholar : PubMed/NCBI
27	Friis T, Engel AM, Bendiksen CD, Larsen LS and Houen G: Influence of levamisole and other angiogenesis inhibitors on angiogenesis and endothelial cell morphology in vitro. Cancers (Basel). 5:762–785. 2013. View Article : Google Scholar : PubMed/NCBI
28	Gabellini C, Trisciuoglio D, Desideri M, et al: Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer. 45:2618–2627. 2009. View Article : Google Scholar : PubMed/NCBI
29	Christofakis EP, Miyazaki H, Rubink DS and Yeudall WA: Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral Oncol. 44:920–926. 2008. View Article : Google Scholar : PubMed/NCBI
30	Wu S, Shang H, Cui L, Zhang Z, Zhang Y, Li Y, Wu J, Li RK and Xie J: Targeted blockade of interleukin-8 abrogates its promotion of cervical cancer growth and metastasis. Mol Cell Biochem. 375:69–79. 2013.PubMed/NCBI
31	Wang Y, Xu RC, Zhang XL, et al: Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 59:145–155. 2012. View Article : Google Scholar : PubMed/NCBI
32	Luppi F, Longo AM, de Boer WI, Rabe KF and Hiemstra PS: Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer. 56:25–33. 2007. View Article : Google Scholar : PubMed/NCBI
33	Ning Y, Manegold PC, Hong YK, et al: Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 128:2038–2049. 2011. View Article : Google Scholar : PubMed/NCBI
34	Kitadai Y, Haruma K, Mukaida N, et al: Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res. 6:2735–2740. 2000.PubMed/NCBI
35	Kido S, Kitadai Y, Hattori N, et al: Interleukin 8 and vascular endothelial growth factor - prognostic factors in human gastric carcinomas? Eur J Cancer. 37:1482–1487. 2001. View Article : Google Scholar : PubMed/NCBI
36	Ju D, Sun D, Xiu L, et al: Interleukin-8 is associated with adhesion, migration and invasion in human gastric cancer SCG-7901 cells. Med Oncol. 29:91–99. 2012. View Article : Google Scholar : PubMed/NCBI
37	Kuai WX, Wang Q, Yang XZ, et al: Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World J Gastroenterol. 18:979–985. 2012. View Article : Google Scholar : PubMed/NCBI
38	Negaard HF, Iversen N, Bowitz-Lothe IM, et al: Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. 23:162–169. 2009. View Article : Google Scholar : PubMed/NCBI
39	Kitadai Y, Haruma K, Sumii K, et al: Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol. 152:93–100. 1998.PubMed/NCBI
40	Shibuya M: Vascular endothelial growth factor and its receptor system: P hysiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 153:13–19. 2013. View Article : Google Scholar : PubMed/NCBI
41	Ayad MW: ElN aggar AA: Angiogenic factor VEGF and its relationship with biological prognostic markers in chronic lymphocytic leukemia. Egypt J Immunol. 17:59–71. 2010.PubMed/NCBI
42	Ido K, Nakagawa T, Sakuma T, et al: Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumors. Neuropathology. 28:604–611. 2008.PubMed/NCBI
43	Xu X, Wang B, Ye C, et al: Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 261:147–157. 2008. View Article : Google Scholar : PubMed/NCBI
44	Giatromanolaki A, Koukourakis MI, Sivridis E, et al: Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res. 6:1917–1921. 2000.PubMed/NCBI
45	Rasheed S, McDonald PJ, Northover JM and Guenther T: Angiogenesis and hypoxic factors in colorectal cancer. Pathol Res Pract. 204:501–510. 2008. View Article : Google Scholar : PubMed/NCBI
46	He LF, Wang TT, Gao QY, et al: Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells. J Biomed Sci. 18:392011. View Article : Google Scholar : PubMed/NCBI
47	Martin D, Galisteo R and Gutkind JS: CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem. 284:6038–6042. 2009. View Article : Google Scholar : PubMed/NCBI
48	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
49	Shibuya M: Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia. Proc Jpn Acad Ser B, Phys Biol Sci. 87:167–178. 2011. View Article : Google Scholar
50	Shibuya M and Claesson-Welsh L: Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 312:549–560. 2006. View Article : Google Scholar : PubMed/NCBI
51	Alitalo K and Carmeliet P: Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 1:219–227. 2002. View Article : Google Scholar : PubMed/NCBI
52	Jakobsson L, Bentley K and Gerhardt H: VEGFRs and Notch, A dynamic collaboration in vascular patterning. Biochem Soc Trans. 37:1233–1236. 2009. View Article : Google Scholar : PubMed/NCBI
53	Kampen KR: The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology. Anticancer Drugs. 23:347–354. 2012. View Article : Google Scholar : PubMed/NCBI
54	Tas F, Duranyildiz D, Oguz H, et al: Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 16:405–411. 2006. View Article : Google Scholar : PubMed/NCBI
55	Hanrahan EO, Lin HY, Kim ES, et al: Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 28:193–201. 2010. View Article : Google Scholar : PubMed/NCBI
56	Petreaca ML, Yao M, Liu Y, Defea K and Martins-Green M: Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell. 18:5014–5023. 2007. View Article : Google Scholar : PubMed/NCBI
57	Chen SU, Chou CH, Lin CW, et al: Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: Dopamine targets their common pathways. Hum Reprod. 25:757–767. 2010. View Article : Google Scholar : PubMed/NCBI
58	Luttun A, Tjwa M and Carmeliet P: Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): Novel therapeutic targets for angiogenic disorders. Ann NY Acad Sci. 979:80–93. 2002. View Article : Google Scholar : PubMed/NCBI